Evidence map›Paper›PMID 30317846›Full record

ArticleThe Korean journal of internal medicine2019

The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction.

Ki Hong Choi, Ga Yeon Lee, Jin-Oh Choi, Eun-Seok Jeon, Hae-Young Lee, Sang Eun Lee, Jae-Joong Kim, Shung Chull Chae, Sang Hong Baek, Seok-Min Kang and 6 more

Open access · goldAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Korean journal of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Exploring the kinetic selectivity of drugs targeting the βPharmacology research & perspectives · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Update on heart failure management and future directions.The Korean journal of internal medicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Ki Hong ChoiDepartment of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ga Yeon LeeDepartment of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jin-Oh ChoiDepartment of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
Eun-Seok JeonDepartment of Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hae-Young LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Sang Eun LeeDepartment of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Jae-Joong KimDepartment of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
Shung Chull ChaeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Sang Hong BaekDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Seok-Min KangDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Dong-Ju ChoiDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Byung-Su YooDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Kye Hun KimHeart Research Center of Chonnam National University, Gwangju, Korea.
Myeong-Chan ChoDepartment of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.
Hyun-Young ParkNational Institute of Health (NIH), Osong, Korea.
Byung-Hee OhDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Sungkyunkwan University · KRSeoul National University Hospital · KRUniversity of Ulsan · KRYonsei University · KRCatholic University of Korea · KRChonnam National University · KRChungbuk National University · KRKorea National Institute of Health · KRKyungpook National University · KRSeoul National University Bundang Hospital · KR

Funding

Korea Centers for Disease Control & Prevention 2010-E63003-00Korea Centers for Disease Control & Prevention 2011-E63002-00Korea Centers for Disease Control & Prevention 2012-E63005-00Korea Centers for Disease Control & Prevention 2013-18 E63003-01Korea Centers for Disease Control & Prevention 2013-E63003-00Korea Centers for Disease Control & Prevention 2013-E63003-02Korea Centers for Disease Control & Prevention 2016-ER6303-00
6 · The paper itself

Abstract

BACKGROUND/

aimsIt is unknown whether different β-blockers (BBs) have variable effects on long-term survival of patients with heart failure with reduced ejection fraction (HFrEF). This study compares the effects of two BBs, carvedilol and bisoprolol, on survival in patients with HFrEF.

methodsThe Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort that includes 5,625 patients who were hospitalized for acute heart failure (AHF). We selected 3,016 patients with HFrEF and divided this study population into two groups: BB at discharge (n = 1,707) or no BB at discharge (n = 1,309). Among patients with BB at discharge, subgroups were formed based on carvedilol prescription (n = 831), or bisoprolol prescription (n = 553). Propensity score matching analysis was performed.

resultsAmong patients who were prescribed a BB at discharge, 60.5% received carvedilol and 32.7% received bisoprolol. There was a significant reduction in allcause mortality in those patients with HFrEF prescribed a BB at discharge compared to those who were not (BB vs. no BB, 26.1% vs. 40.8%; hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.52 to 0.67; p < 0.001). However, there was no significant difference in the rate of all-cause mortality between those receiving different types of BB (carvedilol vs. bisoprolol, 27.5% vs. 23.5%; HR, 1.21; 95% CI, 0.99 to 1.47; p = 0.07). Similar results were observed after propensity score matching analysis (508 pairs, 26.2% vs. 23.8%; HR, 1.10; 95% CI, 0.86 to 1.40; p = 0.47).

conclusionIn the treatment of AHF with reduced EF after hospitalization, mortality benefits of carvedilol and bisoprolol were comparable.

Indexed as

Adrenergic beta-1 Receptor AntagonistsAgedAged, 80 and overBisoprololCarvedilolFemaleHeart FailureHumansMaleMiddle AgedProspective StudiesRecovery of FunctionRegistriesRepublic of KoreaRisk AssessmentRisk FactorsAdrenergic beta-1 Receptor AntagonistsBisoprololCarvedilolBeta-blockerBisoprololCarvedilolHeart failure with reduced ejection fraction

Identifiers

PMID30317846
PMCPMC6718755
OpenAlexW2897795484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.